A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the association between the occurrence of irAEs and overall su...

Повний опис

Бібліографічні деталі
Автори:	Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD
Формат:	Стаття
Мова:	English
Опубліковано:	SAGE Publishing 2022-09-01
Серія:	Cancer Control
Онлайн доступ:	https://doi.org/10.1177/10732748221130576

Схожі ресурси

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
за авторством: Hiroki Hata MS, та інші
Опубліковано: (2020-12-01)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
за авторством: Hideo Oishi, MD, та інші
Опубліковано: (2020-10-01)

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
за авторством: Arthur E. Frankel MD, та інші
Опубліковано: (2019-04-01)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
за авторством: Taichi Miyawaki, MD, та інші
Опубліковано: (2020-06-01)

Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosisCentral MessagePerspective
за авторством: Bilguun Erkhem-Ochir, MD, та інші
Опубліковано: (2021-03-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
за авторством: Samit Chatterjee PhD, та інші
Опубліковано: (2017-07-01)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
за авторством: Tara Davidson, MD, та інші
Опубліковано: (2022-07-01)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
за авторством: Chenxing Zhang, PhD, та інші
Опубліковано: (2020-03-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
за авторством: Daisuke Hazama, MD, PhD, та інші
Опубліковано: (2024-01-01)

A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related MyocarditisNovel Teaching Points
за авторством: Tatsuya Nishikawa, MD, PhD, та інші
Опубліковано: (2022-07-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
за авторством: Kenji Morimoto, MD, PhD, та інші
Опубліковано: (2022-09-01)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
за авторством: Mariana Mirabel, MD, PhD, та інші
Опубліковано: (2020-09-01)

A Modified Method for the Quantification of Immune Checkpoint Ligands on Exosomes from Human Serum using Flow Cytometry
за авторством: Alan Guillermo Alejandre Gonzalez PhD, та інші
Опубліковано: (2023-05-01)

A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8
за авторством: Amanda Leiter, MD, MSCR, та інші
Опубліковано: (2020-07-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
за авторством: Yasunori Murata, MD, PhD, та інші
Опубліковано: (2023-12-01)

The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
за авторством: Fatih Kus MD, та інші
Опубліковано: (2024-09-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
за авторством: Shiting Xu, MD, та інші
Опубліковано: (2022-04-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
за авторством: Yuto Terashima, MD, та інші
Опубліковано: (2023-11-01)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
за авторством: Xinlun Dai MD, та інші
Опубліковано: (2020-08-01)

Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis
за авторством: Lianghui Zhang MS, та інші
Опубліковано: (2024-08-01)

A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis
за авторством: Mahdieh Azizi, PhD, та інші
Опубліковано: (2024-01-01)

Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma
за авторством: Qiang Liu PhD, та інші
Опубліковано: (2024-04-01)

Comprehensive Characterization of Cardiac, Skeletal and Diaphragmatic Myotoxicity Using CMR in Patients with Immune Checkpoint Inhibitor Therapy and Relation to Outcomes
за авторством: Etienne Charpentier, MD, та інші
Опубліковано: (2024-01-01)

Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors
за авторством: Jack M. Qian, MD, та інші
Опубліковано: (2022-03-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
за авторством: Mandy Jongbloed, MD, та інші
Опубліковано: (2025-03-01)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors∗
за авторством: Dorothy M. Gujral, PhD, та інші
Опубліковано: (2020-02-01)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
за авторством: Ying Teng PhD, та інші
Опубліковано: (2022-03-01)

IgA pemphigus as an immune checkpoint inhibitor-associated skin manifestation
за авторством: Tristan V.M. Bruijn, MD, та інші
Опубліковано: (2024-05-01)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
за авторством: Kana Hashimoto, MD, та інші
Опубліковано: (2024-11-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
за авторством: Natalie Bourand, MS, та інші
Опубліковано: (2025-02-01)

Inhibits Murine Leukemia WEHI-3 Cells and Promotes Immune Response In Vivo
за авторством: Hsin-Ling Yang PhD, та інші
Опубліковано: (2017-09-01)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
за авторством: Roger Y. Kim, MD, та інші
Опубліковано: (2021-06-01)

Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review
за авторством: Benjamin M.P. Elyan, MBChB, та інші
Опубліковано: (2023-07-01)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
за авторством: Marco Tagliamento, MD, та інші
Опубліковано: (2023-01-01)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
за авторством: Denis L. Jardim MD, PhD, та інші
Опубліковано: (2018-12-01)

Seeking “protective” and “harmful” immune genes during chronic HIV-1 infection by transcriptome analysis
за авторством: Lingyan Zhu, PhD, та інші
Опубліковано: (2018-09-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
за авторством: Alicia Quilez, MD, та інші
Опубліковано: (2020-03-01)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation
за авторством: Jia-Jun Wu, MD, та інші
Опубліковано: (2022-06-01)

The Value of Combined Detection of Megakaryocyte and Platelet Parameters for the Diagnosis of Primary Immune Thrombocytopenia
за авторством: Weiwei Wang MS, та інші
Опубліковано: (2022-08-01)

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
за авторством: Sakeena Fatima, BA, та інші
Опубліковано: (2018-04-01)